U. S. equity futures traded mixed on Monday as investors weighed renewed military exchanges between Iran and Israel alongside growing doubts over the sustainability of the artificial intelligence-driven market rally.
U. S. equity futures traded mixed on Monday as investors weighed renewed military exchanges between Iran and Israel alongside growing doubts over the sustainability of the artificial intelligence-driven market rally.
Nvidia (NASDAQ: NVDA) has been the undisputed winner of the artificial intelligence boom. Its graphics processing units (GPUs) became the foundation of modern AI infrastructure, powering everything from ChatGPT to autonomous driving systems. And Nvidia's data center revenue has exploded over the past few years as cloud infrastructure giants raced to build massive new AI clusters packed with thousa...
Nvidia (NASDAQ: NVDA) has been the undisputed winner of the artificial intelligence boom. Its graphics processing units (GPUs) became the foundation of modern AI infrastructure, powering everything from ChatGPT to autonomous driving systems. And Nvidia's data center revenue has exploded over the past few years as cloud infrastructure giants raced to build massive new AI clusters packed with thousands of GPUs. But the AI infrastructure market is evolving, and the next phase may not be dominated solely by ever-larger GPU clusters. Continue reading
Palo Alto Networks (NASDAQ: PANW) stock soared in May's trading , rising 57.1% across the stretch . The S&P 500 gained 5.2% across the stretch, and the Nasdaq Composite was up 8.4%. May was a strong month for growth stocks, and Palo Alto saw strong gains as investors placed bullish bets across the cybersecurity industry. Despite a pullback in June's trading, the stock is still up roughly 48% year ...
Palo Alto Networks (NASDAQ: PANW) stock soared in May's trading , rising 57.1% across the stretch . The S&P 500 gained 5.2% across the stretch, and the Nasdaq Composite was up 8.4%. May was a strong month for growth stocks, and Palo Alto saw strong gains as investors placed bullish bets across the cybersecurity industry. Despite a pullback in June's trading, the stock is still up roughly 48% year to date. Image source: Getty Images. Continue reading
Goldman And UBS Preview Apple's WWDC: AI Siri Takes Center Stage Apple's annual Worldwide Developers Conference (WWDC) begins this afternoon at 1 p.m. EST at Apple Park in Cupertino, Calif. Ahead of WWDC, Goldman analysts led by Michael Ng provided clients with a preview of what to expect, including the unveiling of a long-delayed AI-enhanced Siri and operating system version "27" across iOS, macO...
Goldman And UBS Preview Apple's WWDC: AI Siri Takes Center Stage Apple's annual Worldwide Developers Conference (WWDC) begins this afternoon at 1 p.m. EST at Apple Park in Cupertino, Calif. Ahead of WWDC, Goldman analysts led by Michael Ng provided clients with a preview of what to expect, including the unveiling of a long-delayed AI-enhanced Siri and operating system version "27" across iOS, macOS, watchOS, tvOS, and visionOS. The new AI-enhanced Siri will include many delayed features from WWDC24, such as on-screen awareness, personal context, and deeper integration across apps, including Messages, Calendar, Photos, and Notes. "We view these new features as key demand drivers for the iPhone and other products, which should help extend the strong revenue momentum realized to date (e.g., iPhone revenue +23% YoY in F1H26)," Ng wrote in the note. Expected WWDC announcements: AI-enhanced Siri launch timing & feature details. After announcing AI-enhanced Siri at WWDC in 2024 and seeing subsequent delays, we expect Apple to share updated details on AI Siri's launch timeline and capabilities. Launch timing: During Apple's F2Q26 earnings call, the company stated it expects to launch personalized Siri this year (C2026). We expect Apple to confirm AI Siri should launch with iOS 27 in September 2026 alongside the premium iPhone 18 family launch. AI Siri feature details: First, AI-enhanced Siri should have greater on-screen awareness (e.g., using information across iOS Apps including Messages, Calendar, Photos, Notes), which should allow it to provide more detailed, personalized answers to queries/prompts. Second, Apple likely will announce that users will have the ability to choose between various model providers to power AI features (Siri, Image Playground, Writing Tools), per Bloomberg. Third, Apple likely will announce a new standalone Siri app for users to interact in a chatbot-like manner. Additional AI-driven & ancillary features. Aside from AI Siri, per Bloomberg, Appl...
A leveraged exchange-traded fund tied to SK Hynix Inc. surged 50% on Monday despite a drop of nearly 8% in the underlying stock, a dislocation the fund house later attributed to a lack of liquidity in its market-making system. The KIM ACE SK Hynix Single Stock Leverage ETF closed at an all-time high level of 30,000 won on Monday, even as South Korean stocks plunged amid a selloff in memory-chip ma...
A leveraged exchange-traded fund tied to SK Hynix Inc. surged 50% on Monday despite a drop of nearly 8% in the underlying stock, a dislocation the fund house later attributed to a lack of liquidity in its market-making system. The KIM ACE SK Hynix Single Stock Leverage ETF closed at an all-time high level of 30,000 won on Monday, even as South Korean stocks plunged amid a selloff in memory-chip makers Samsung Electronics Co. and SK Hynix. The fund is designed to deliver twice the daily move in SK Hynix’s shares, which should have translated into a loss of roughly 15% on the day. Other single-stock leveraged ETFs tracking SK Hynix closed lower within the expected range. Korea Investment Management Co. , which manages the KIM ACE ETF, attributed the trading anomaly to a breakdown in its liquidity provider’s quoting system. “Just before the market close, when liquidity providers are not obligated to submit quotes, the LP bid-ask spread widened,” the fund house said via a text message. “As prices became volatile, buy orders placed at market price by investors were executed, leading to a sharp rise” in the price of the ETF, it added. The anomaly came during a turbulent session for Korean equities. The benchmark Kospi tumbled nearly 9% intraday, triggering a 20-minute trading halt by the stock exchange shortly after market open, as investors pulled back from the artificial intelligence trade. Trading for the small-cap Kosdaq was also suspended in the afternoon. Read more: Korean Stocks Tumble as Unwinding AI Trades Threaten Bull Run “Such dislocations are rare but not unprecedented,” said Jung In Yun , chief executive officer at Fibonacci Asset Management. “ETFs typically rely on market makers to keep prices aligned with underlying holdings. However, during the closing auction, those safeguards can weaken, particularly in niche products with limited trading volume.” The KIM ACE SK Hynix is one among the more than dozen single-stock leveraged ETFs tied to chipmakers that w...
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects. The Danish drugmaker said that while its drug survodutide met its key targets in a late-stage study , 19% of patients dropped out of the study due to gastrointestinal events, compared to 2.9% on placebo. "Safety/tolerability...
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects. The Danish drugmaker said that while its drug survodutide met its key targets in a late-stage study , 19% of patients dropped out of the study due to gastrointestinal events, compared to 2.9% on placebo. "Safety/tolerability remains the key issue," said Barclays analysts in a note on Monday. The high discontinuation rate, with more than 40% of patients reporting vomiting, might limit the drug's commercial potential as a treatment for obesity or those suffering from fatty liver disease, the analysts added. Shares of Zealand Pharma were last seen down 24%, adding to nearly 50% drop year-to-date. Zealand's stock plummets after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics' The full survodutide data comes about three months after Zealand stock suffered its worst day on record when a trial of another of its experimental anti-obesity drugs disappointed investors with lower-than-expected weight loss statistics. Analysts at Citi wrote in a note on Monday: "A 19% treatment discontinuation rate due to... adverse events... is not a rounding error, and nausea, vomiting, diarrhea, and constipation incidence at the levels reported here sit well above what we consider commercially viable against [rival drugs] tirzepatide and semaglutide." Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.